Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised SCA in connection with the financing of the investment in the Obbola kraftliner mill
Mandate

Vinge has advised SCA in connection with the financing of the investment in the Obbola kraftliner mill

July 22, 2020 Banking and Finance

The total investment for Svenska Cellulosa Aktiebolaget SCA (publ) (”SCA”) amounts to SEK 7.5 billion over a five-year period.

The investment will mainly be financed by operating cash flow, complemented by regular group financing activities which consists of, inter alia, the entry into of a facility agreement with export financing elements (including an export financing guarantee from Euler Hermes Aktiengesellschaft). Further details regarding the export financing have not been published.

SCA was introduced on the Stockholm Stock Exchange in 1950 and is today traded on, inter alia, Nasdaq Stockholm. SCA’s press release and further information on the investment is found here.

Vinge’s team primarily consisted of Mikael Ståhl and Ludvig Wettergren.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025